Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to advance its lead multiple sclerosis (MS) candidate, Lucid-MS, into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in individuals with MS, using both clinical and radiological endpoints. With trial start-up activities already underway, including site selection, patient enrollment and drug administration are expected to begin expeditiously.
What distinguishes Lucid-MS from existing MS therapies is its mechanism of action. While current treatments primarily focus on modulating the immune system to reduce inflammation, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination—the process by which the protective myelin sheath around nerve fibers is damaged. The candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical studies have demonstrated that Lucid-MS can prevent and even reverse myelin breakdown, offering a potential avenue to address the underlying pathology of MS rather than merely managing symptoms.
The FDA clearance is a significant milestone for Quantum BioPharma, as it transitions Lucid-MS from early-stage research to a pivotal phase of clinical testing. The company previously reported that Lucid-MS exhibited a favorable safety profile and was well tolerated in Phase 1 trials involving healthy participants. As of March 31, 2026, Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments, which may support the upcoming trial and ongoing operations.
Multiple sclerosis is a chronic, often disabling disease that affects the central nervous system, with current therapies offering limited efficacy in halting disease progression. If Lucid-MS proves successful in Phase 2, it could represent a paradigm shift in MS treatment by targeting the root cause of myelin loss. The potential to restore neurological function would address a significant unmet need for the millions of people living with MS worldwide.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative, metabolic, and alcohol misuse disorders. Lucid-MS is developed through its wholly owned subsidiary, Lucid Psycheceuticals Inc., and is a patented new chemical entity. The company's broader pipeline reflects a commitment to advancing science where traditional approaches have fallen short. For more information on the company and its developments, visit Quantum BioPharma's newsroom.
The forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. Investors are encouraged to review the company's filings with the SEC for a comprehensive discussion of these factors.
